Agam Ahmad, Vadsholt David, Kragholm Kristian, Østergaard Lauge Klement Moltke, Stæhr Peter Bisgaard, Nielsen Gitte, Vadmann Henrik
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Aalborg University Hospital, Denmark.
Int J Cardiol Cardiovasc Risk Prev. 2025 Jun 7;26:200444. doi: 10.1016/j.ijcrp.2025.200444. eCollection 2025 Sep.
This study aims to identify three-month and one year mortality rate, LDL level and adherence to guideline-recommended medication in patients with myocardial infarct (MI) receiving cardiac rehabilitation (CR) compared to patients who do not.
In this retrospective study, patients hospitalized in North Denmark Regional Hospital in Hjoerring (capture population 200.000) with acute coronary syndrome between January 1st, 2017, to December 31st, 2021, were included. Baseline characteristics, initial treatment of revascularization and all-cause mortality were examined through the Danish National Patient Registry, the Regional Cardiac Rehabilitation Database, and medical chart review. Patients were grouped by revascularization (yes/no) during hospitalization and CR. Adjusted Cox proportional regression model was used to assess differences in mortality and LDL levels.
A total of 1209 myocardial infarction (MI) survivors were included in this study. A total of 1209 myocardial infarction (MI) survivors were included. Significant LDL reductions at 6- and 12-month follow-ups were observed in patients receiving both cardiac rehabilitation (CR) and lipid-modifying therapy at baseline (p = .001), but not in those without CR. In revascularized patients, use of multiple antithrombotic agents was lower in the no CR group at three months (57.1 % vs 78.8 %, p = .002) and one year (60 % vs 78.5 %, p = .010). Three-month mortality rate was higher among patients who did not undergo CR, both in the revascularization group (19 % vs 2 %, p = 0.001) and the non-revascularization group (18 % vs 3 %, p = 0.001).
Patients undergoing CR were associated with lower LDL-levels, higher adherence to guideline-recommended medication and lower mortality rate at three-month follow-up.
本研究旨在确定接受心脏康复(CR)的心肌梗死(MI)患者与未接受心脏康复的患者相比,三个月和一年的死亡率、低密度脂蛋白(LDL)水平以及对指南推荐药物的依从性。
在这项回顾性研究中,纳入了2017年1月1日至2021年12月31日期间在霍森斯北丹麦地区医院住院(捕获人群20万)的急性冠状动脉综合征患者。通过丹麦国家患者登记处、地区心脏康复数据库和病历审查来检查基线特征、初始血运重建治疗和全因死亡率。患者按住院期间的血运重建情况(是/否)和心脏康复情况进行分组。采用调整后的Cox比例回归模型来评估死亡率和低密度脂蛋白水平的差异。
本研究共纳入1209名心肌梗死(MI)幸存者。在基线时同时接受心脏康复(CR)和降脂治疗的患者中观察到在6个月和12个月随访时低密度脂蛋白有显著降低(p = 0.001),但未接受心脏康复的患者中未观察到。在接受血运重建的患者中,未接受心脏康复组在三个月时使用多种抗血栓药物的比例较低(57.1%对78.8%,p = 0.002),在一年时也较低(60%对78.5%,p = 0.010)。未接受心脏康复的患者三个月死亡率较高,在血运重建组(19%对2%,p = 0.001)和非血运重建组(18%对3%,p = 0.001)均如此。
接受心脏康复的患者在三个月随访时低密度脂蛋白水平较低、对指南推荐药物的依从性较高且死亡率较低。